By: Matt Wirz
MAPS needs the money to fund the final stages of its application for regulatory approval to sell MDMA, also known as Ecstasy, to treat post-traumatic stress disorder.
Credit reporter, Debt Dictator, Brooklyn BikerDad. Opinions are my own.
International
Matt Wirz's coverage primarily focuses on finance, particularly investment analysis with a significant emphasis on the U.S. market. He would likely be interested in pitches that offer unique perspectives or insights related to the U.S. economy, credit markets, and developments within Wall Street and banking.
Given Matt's focus on investment analysis, he may be receptive to expert commentary from individuals with deep knowledge of financial instruments and markets trends affecting the U.S. Specifically, he might appreciate sources who can provide detailed insight into emerging investment trends or shifts within the finance industry.
Pitches relevant to topics such as asset management strategies, changes in risk assessment methodologies by banks, and analyses of corporate funding through private funds could align well with his coverage interests.
This information evolves through artificial intelligence and human feedback. Improve this profile .